Ryan Spencer

Ryan Spencer is the CEO of Dynavax Technologies, the Emeryville biotech behind HEPLISAV-B and the CpG 1018 adjuvant. He joined as an interim controller in 2005, climbed for fourteen years through finance, IR, and commercial roles, and took the top job in December 2019. Under him, Dynavax supplied adjuvant for nearly a billion COVID-19 vaccine doses and, in December 2025, agreed to be acquired by Sanofi for roughly $2.2 billion.